Innovations in Pathophysiology, Diagnosis, Genomic Medicine and State-of-the-Art Treatment Approaches in Pediatric Acute Lymphoblastic Leukemia in the Twenty-First Century DOI Creative Commons

Nawaf Alanazi,

Sarah AlMukhaylid,

Zafar Iqbal

et al.

IntechOpen eBooks, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 15, 2024

Innovative advancements in the twenty-first-century technologies have revealed new genetic, immunological, and cellular biological mechanisms that contribute to understanding biology pathogenesis of pediatric as well adulthood diseases. These sparked a significant revolution diagnosis, prognosis, treatment different cancers including hematological malignancies, particularly leukemia. Numerous molecular genetic assays been developed select optimal drugs clinical protocols for leukemia patients. This personalized approach aims achieve better outcomes with reduced drug side effects. Genomic medicine has made basic testing necessary every clinic hospital. book provides an account classical novel developments acute lymphoblastic (ALL) most common childhood malignancy, resulted from state-of-the-art cell biological, immunological research during last three decades. Moreover, it also deep insights into innovation differential risk stratification, patient-tailored treatment, accurate therapeutic follow-up timely interventions recent era modern science technology innovations twenty-first century fascinatingly improved outcome this deadly disease childhood.

Language: Английский

Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet? DOI
Markus F. Neurath, Bruce E. Sands, Florian Rieder

et al.

Gut, Journal Year: 2024, Volume and Issue: 74(1), P. 9 - 14

Published: July 17, 2024

Despite significant advances in biologic and small molecule treatments the emergence of combination therapies to treat inflammatory bowel diseases (IBD) a large unmet need remains control intestinal inflammation. New approaches targeting several pathways simultaneously with favorable safety profile agents that trigger anti-inflammatory drive durable resolution inflammation are needed. This article discusses novel cellular immunotherapies immune cell depleting IBD, including CAR-T approaches, Tr1 T regulatory (Treg) cells antibodies such as rosnilimab. These have potential overcome current therapeutic limitations treatment IBD.

Language: Английский

Citations

8
Multifaceted Roles of Nursing in the Care of Patients Receiving CAR T-cell Therapy for Pediatric Refractory or Relapsed Acute Lymphoblastic Leukemia DOI Creative Commons
Colleen Callahan,

Lauren Haas,

Laura T. Smith

et al.

Journal of Modern Nursing Practice and Research, Journal Year: 2025, Volume and Issue: 5(1), P. 2 - 2

Published: Jan. 16, 2025

Pediatric acute lymphoblastic leukemia (ALL) is the most common cancer in children. Survival rates after initial diagnosis of ALL are quite high, however survival for patients with refractory or relapsed remain poor despite intensive chemotherapy, indicating need novel therapies. Treatment pediatric and has undergone a dramatic change over past twelve years due to success targeted immunotherapy. In particular, chimeric antigen receptor-T (CAR-T) cell therapy shown great promise treatment ALL. Due encouraging results, there increasing numbers trials utilizing this treatment. Patients families have been given hope introduction progress innovative therapy. Expert nursing care crucial successful patient outcomes. Nurses integral management, care, monitoring CAR-T patients, ensuring study guidelines followed providing continuity. potential cause severe toxicities. Therefore, nurses must be educated so that they can provide safe effectively educate regarding associated risks. article we describe process focus on multiple roles nurse along highlighting collaborative relationships other disciplines.

Language: Английский

Citations

0
Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs DOI Creative Commons

Guo Shu-hua,

Xiaozhi Xi

Biomarker Research, Journal Year: 2025, Volume and Issue: 13(1)

Published: March 11, 2025

Abstract CAR-T cells are genetically modified T lymphocytes that express chimeric antigen receptors (CAR) on their surfaces. These enable to recognize specific antigens target cells, triggering a response leads targeted cytotoxicity. While therapy has effectively treated various blood cancers, it faces significant challenges in addressing solid tumors. include identifying precise tumor antigens, overcoming evasion, and enhancing the function of within microenvironment. Single domain antibody, versatile tools with low immunogenicity, high stability, strong affinity, show promise for improving efficacy against By these challenges, single antibody potential overcome limitations associated ScFv antibody-based therapies. This review highlights benefits utilizing therapy, particularly targeting explores development strategies could advance field.

Language: Английский

Citations

0
Immune-mediated neurological syndromes associated with childhood cancers DOI Creative Commons
Thomas Rossor, Sanjay Tewari,

Jon Gadian

et al.

European Journal of Paediatric Neurology, Journal Year: 2024, Volume and Issue: 53, P. 174 - 181

Published: Nov. 1, 2024

Language: Английский

Citations

0
Efficacy and safety of blinatumomab for the treatment of patients relapsing after allogeneic hematopoietic cell transplantation: a systemic review and meta-analysis DOI Creative Commons

Huai-Peng Guo,

Ying Liu, Lei Kang

et al.

Hematology, Journal Year: 2024, Volume and Issue: 29(1)

Published: Nov. 18, 2024

We aim to evaluate the efficacy and safety of blinatumomab for treatment post-transplant relapse patients with acute lymphoblastic leukemia (ALL).

Language: Английский

Citations

0
Innovations in Pathophysiology, Diagnosis, Genomic Medicine and State-of-the-Art Treatment Approaches in Pediatric Acute Lymphoblastic Leukemia in the Twenty-First Century DOI Creative Commons

Nawaf Alanazi,

Sarah AlMukhaylid,

Zafar Iqbal

et al.

IntechOpen eBooks, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 15, 2024

Innovative advancements in the twenty-first-century technologies have revealed new genetic, immunological, and cellular biological mechanisms that contribute to understanding biology pathogenesis of pediatric as well adulthood diseases. These sparked a significant revolution diagnosis, prognosis, treatment different cancers including hematological malignancies, particularly leukemia. Numerous molecular genetic assays been developed select optimal drugs clinical protocols for leukemia patients. This personalized approach aims achieve better outcomes with reduced drug side effects. Genomic medicine has made basic testing necessary every clinic hospital. book provides an account classical novel developments acute lymphoblastic (ALL) most common childhood malignancy, resulted from state-of-the-art cell biological, immunological research during last three decades. Moreover, it also deep insights into innovation differential risk stratification, patient-tailored treatment, accurate therapeutic follow-up timely interventions recent era modern science technology innovations twenty-first century fascinatingly improved outcome this deadly disease childhood.

Language: Английский

Citations

0